The molecular genetic basis for hypertrophic cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 33, Issue 4, 2001, Pages 655-670

  Marian, A J ^a   Roberts, R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Genetics; Hypertrophy; Mutation; Transgenic animals

Indexed keywords

MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; TROPONIN;

CONFERENCE PAPER; GENE MUTATION; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; SARCOMERE; SUDDEN DEATH; TRANSGENIC ANIMAL;

EID: 0034976642     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2001.1340     Document Type: Conference Paper

References (113)

1. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles
2. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults
3. Hypertrophic cardiomyopathy
4. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990
5. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy
6. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death
7. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
8. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1
9. A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation
10. The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product
11. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles
12. Molecular genetic studies of familial hypertrophic cardiomyopathy
13. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy
14. Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene
15. Genotype-phenotype analysis in four families with mutations in beta-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy
16. A novel deletion mutation in the beta-myosin heavy chain gene found in Japanese patients with hypertrophic cardiomyopathy
17. Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy
18. A previously undescribed de novo insertion-deletion mutation in the beta myosin heavy chain gene in a kindred with familial hypertrophic cardiomyopathy
19. Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy
20. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy
21. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy
22. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy
23. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy
24. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart
25. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere
26. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy
27. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy
28. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle
29. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy
30. Structural analysis of the titin gene in hypertrophic cardiomyopathy: Identification of a novel disease gene
31. Cardiomyopathies and mitochondrial DNA mutations
32. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu-Val mutation and a 403Arg - Gln mutation
33. Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations
34. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy
35. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy
36. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene
37. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the betamyosin heavy chain genes
38. Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy
39. Homozygous mutation in cardiac troponin T: Implications for hypertrophic cardiomyopathy
40. A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes
41. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death
42. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy
43. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation
44. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
45. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy
46. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy
47. Single myosin molecule mechanics: Piconewton forces and nanometre steps
48. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy
49. Cardiac myosin binding protein C
50. A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy
51. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: A modulator of cardiac contraction?
52. The troponin complex and regulation of muscle contraction
53. Troponin and tropomyosin: Proteins that switch on and tune in the activity of cardiac myofilaments
54. Myosin light chain phosphorylation in vertebrate striated muscle: Regulation and function
55. Skeletal muscle myosin light chains are essential for physiological speeds of shortening
56. Impairment of muscle function caused by mutations of phosphorylation sites in myosin regulatory light chain
57. Regulation of human heart contractility by essential myosin light chain isoforms
58. Transgenic remodeling of the regulatory myosin light chains in the mammalian heart
59. Point mutations in human beta cardiac myosin heavy chain have differential effects on sarcomeric structure and assembly: An ATP binding site change disrupts both thick and thin filaments, whereas hypertrophic cardiomyopathy mutations display normal assembly
60. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes
61. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy
62. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes
63. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction
64. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy
65. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins
66. Ca2+ -sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy
67. Ca2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy
68. Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility
69. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy
70. Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication
71. Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome
72. Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy
73. Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy
74. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy
75. Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin. Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility
76. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy
77. Isometric tension and mutant myosin heavy chain content in single skeletal myofibers from hypertrophic cardiomyopathy patients
78. An alpha-cardiac myosin heavy chain gene mutation impairs contraction and relaxation function of cardiac myocytes
79. Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility
80. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action
81. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: Insights into disease pathogenesis and troponin function
82. A mouse model of familial hypertrophic cardiomyopathy
83. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice
84. Cardiac troponin T mutations result in allelespecific phenotypes in a mouse model for hypertrophic cardiomyopathy
85. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction
86. Cardiac myosin heavy chains lacking the light chain binding domain cause hypertrophic cardiomyopathy in mice
87. The stretch-activation response may be critical to the proper functioning of the mammalian heart
88. Transgenic rat hearts expressing a human cardiac troponin T deletion reveal diastolic dysfunction and ventricular arrhythmias
89. A transgenic rabbit model for human hypertrophic cardiomyopathy
90. The pathogenests of familial hypertrophic cardiomyopathy: Early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation
91. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy
92. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy
93. Diastolic dysfunction and altered energetics in the alpha-MHC403/+ mouse model of familial hypertrophic cardiomyopathy
94. Familial hypertrophic cardiomyopathy mice display gender differences in electrophysiological abnormalities
95. Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice
96. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy
97. Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q(92), responsible for human hypertrophic cardiomyopathy
98. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy
99. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy, Characterization of cardiac transcript and protein
100. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart
101. Targeted ablation of the murine alpha-tropomyosin gene
102. Molecular and physiological effects of alpha-tropomyosin ablation in the mouse
103. Overexpression of transforming growth factorbeta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy
104. Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy
105. Endothelin-1 and its receptor in hypertrophic cardiomyopathy
106. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy
107. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy
108. Abnormal contractile function in transgenic mice expressing an FHC-linked troponin T (179N) mutation
109. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice
110. In vivo analysis of an essential myosin light chain mutation linked to familial hypertrophic cardiomyopathy
111. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy